Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors
JL Woodhead, WJ Brock, SE Roth… - Toxicological …, 2017 - academic.oup.com
Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries
for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD…
for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD…
Editor's highlight: Candidate risk factors and mechanisms for tolvaptan-induced liver injury are identified using a collaborative cross approach
M Mosedale, Y Kim, WJ Brock, SE Roth… - Toxicological …, 2017 - academic.oup.com
Clinical trials of tolvaptan showed it to be a promising candidate for the treatment of
Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for …
Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for …
miR-122 release in exosomes precedes overt tolvaptan-induced necrosis in a primary human hepatocyte micropatterned coculture model
Idiosyncratic drug-induced liver injury (IDILI) is thought to often result from an adaptive immune
attack on the liver. However, it has been proposed that the cascade of events culminating …
attack on the liver. However, it has been proposed that the cascade of events culminating …
Inhibition of human hepatic bile acid transporters by tolvaptan and metabolites: contributing factors to drug-induced liver injury?
…, KM Freeman, M Pan, WJ Brock… - Toxicological …, 2016 - academic.oup.com
Tolvaptan is a vasopressin V 2 -receptor antagonist that has shown promise in treating
Autosomal Dominant Polycystic Kidney Disease (ADPKD). Tolvaptan was, however, associated …
Autosomal Dominant Polycystic Kidney Disease (ADPKD). Tolvaptan was, however, associated …
Quantitative systems toxicology modeling predicts that reduced biliary efflux contributes to tolvaptan hepatotoxicity
JJ Beaudoin, WJ Brock, PB Watkins… - Clinical …, 2021 - Wiley Online Library
Patients with autosomal dominant polycystic kidney disease (ADPKD) exhibit enhanced
susceptibility to tolvaptan hepatotoxicity relative to other patient populations. In a rodent model …
susceptibility to tolvaptan hepatotoxicity relative to other patient populations. In a rodent model …
Oral repeat dose and reproductive toxicity of the chlorinated flame retardant Dechlorane Plus
WJ Brock, RE Schroeder, CA McKnight… - … journal of toxicology, 2010 - journals.sagepub.com
This study consisted of a 28-day oral repeat dose (repeat dose toxicity [RDT]) phase and a
developmental and reproductive (developmental and reproductive toxicity [DART]) phase with …
developmental and reproductive (developmental and reproductive toxicity [DART]) phase with …
Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats
EJ Tillman, WJ Brock, T Rolph - British Journal of …, 2022 - Wiley Online Library
Background and Purpose Analogues of fibroblast growth factor 21 (FGF21) demonstrate
diverse metabolic benefits in preclinical models of type 2 diabetes, dyslipidaemia and non‐…
diverse metabolic benefits in preclinical models of type 2 diabetes, dyslipidaemia and non‐…
Bile acids as potential biomarkers to assess liver impairment in polycystic kidney disease
WJ Brock, JJ Beaudoin, JR Slizgi… - … journal of toxicology, 2018 - journals.sagepub.com
Polycystic kidney disease is characterized by the progressive development of kidney cysts
and declining renal function with frequent development of cysts in other organs including the …
and declining renal function with frequent development of cysts in other organs including the …
Food safety: risk assessment methodology and decision-making criteria
WJ Brock, JV Rodricks, A Rulis… - … journal of toxicology, 2003 - journals.sagepub.com
As our scientific technology grows, risk assessment methods become more complex and,
therefore, open to greater scientific debate. Risk assessment has always been a part of the …
therefore, open to greater scientific debate. Risk assessment has always been a part of the …
Altered expression and function of hepatic transporters in a rodent model of polycystic kidney disease
…, JJ Beaudoin, K Ito, D Fu, SE Roth, WJ Brock… - Drug Metabolism and …, 2019 - ASPET
Autosomal dominant polycystic kidney disease (ADPKD) is a common form of inherited
polycystic kidney disease (PKD) and is a leading cause of kidney failure. Fluid-filled cysts …
polycystic kidney disease (PKD) and is a leading cause of kidney failure. Fluid-filled cysts …